Dr. Lior Shaltiel reports
NUREXONE ANNOUNCES SECURITIES FOR DEBT SETTLEMENT
Nurexone Biologic Inc. has agreed to settle debts in the amount of $46,523.69 with the issuance of 122,430 common shares of the company at a deemed price of 38 cents per share.
These debts were incurred prior to the recent reverse takeover transaction following which Nurexone began trading under the new name Nurexone Biologic Inc. with the trading symbol NRX. The common shares will be issued upon acceptance by the TSX Venture Exchange. The common shares issued will be subject to a four-month-plus-one-day hold period pursuant to the policies of the TSX Venture Exchange.
About Nurexone Biologic Inc.
Nurexone is a TSX Venture Exchange-listed pharmaceutical company that is, through its wholly owned subsidiary, Nurexone Biologic Ltd., developing a platform for biologically guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion Israel Institute of Technology. Nurexone intends to translate the treatment to humans, and the company holds an exclusive worldwide licence from the Technion and Tel Aviv University for the development and commercialization of the technology.
We seek Safe Harbor.
© 2022 Canjex Publishing Ltd. All rights reserved.